These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 31012222)
1. Dimeric C34 Derivatives Linked through Disulfide Bridges as New HIV-1 Fusion Inhibitors. Kobayakawa T; Ebihara K; Honda Y; Fujino M; Nomura W; Yamamoto N; Murakami T; Tamamura H Chembiochem; 2019 Aug; 20(16):2101-2108. PubMed ID: 31012222 [TBL] [Abstract][Full Text] [Related]
2. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection. Lai W; Wang C; Yan J; Liu H; Zhang W; Lin B; Xi Z Bioorg Med Chem; 2020 Feb; 28(4):115214. PubMed ID: 31932193 [TBL] [Abstract][Full Text] [Related]
3. Bivalent HIV-1 fusion inhibitors based on peptidomimetics. Kobayakawa T; Ebihara K; Tsuji K; Kawada T; Fujino M; Honda Y; Ohashi N; Murakami T; Tamamura H Bioorg Med Chem; 2020 Dec; 28(24):115812. PubMed ID: 33157478 [TBL] [Abstract][Full Text] [Related]
5. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851 [TBL] [Abstract][Full Text] [Related]
6. Multimerized CHR-derived peptides as HIV-1 fusion inhibitors. Nomura W; Hashimoto C; Suzuki T; Ohashi N; Fujino M; Murakami T; Yamamoto N; Tamamura H Bioorg Med Chem; 2013 Aug; 21(15):4452-8. PubMed ID: 23800723 [TBL] [Abstract][Full Text] [Related]
7. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure. Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527 [TBL] [Abstract][Full Text] [Related]
8. [The current progress in the development of HIV-1 fusion inhibitors]. Shi WG; Jia QY; Liu KL Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428 [TBL] [Abstract][Full Text] [Related]
9. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors. Zhu Y; Ding X; Yu D; Chong H; He Y J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552 [TBL] [Abstract][Full Text] [Related]
10. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV. Gustchina E; Hummer G; Bewley CA; Clore GM J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842 [TBL] [Abstract][Full Text] [Related]
11. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018 [TBL] [Abstract][Full Text] [Related]
12. Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34. Wang LX; Song H; Liu S; Lu H; Jiang S; Ni J; Li H Chembiochem; 2005 Jun; 6(6):1068-74. PubMed ID: 15883971 [TBL] [Abstract][Full Text] [Related]
13. Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. Stoddart CA; Nault G; Galkina SA; Thibaudeau K; Bakis P; Bousquet-Gagnon N; Robitaille M; Bellomo M; Paradis V; Liscourt P; Lobach A; Rivard ME; Ptak RG; Mankowski MK; Bridon D; Quraishi O J Biol Chem; 2008 Dec; 283(49):34045-52. PubMed ID: 18809675 [TBL] [Abstract][Full Text] [Related]
14. Peptide and non-peptide HIV fusion inhibitors. Jiang S; Zhao Q; Debnath AK Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159 [TBL] [Abstract][Full Text] [Related]
15. The N-Terminal T-T Motif of a Third-Generation HIV-1 Fusion Inhibitor Is Not Required for Binding Affinity and Antiviral Activity. Chong H; Qiu Z; Su Y; He Y J Med Chem; 2015 Aug; 58(16):6378-88. PubMed ID: 26256053 [TBL] [Abstract][Full Text] [Related]
16. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket. Stewart KD; Huth JR; Ng TI; McDaniel K; Hutchinson RN; Stoll VS; Mendoza RR; Matayoshi ED; Carrick R; Mo H; Severin J; Walter K; Richardson PL; Barrett LW; Meadows R; Anderson S; Kohlbrenner W; Maring C; Kempf DJ; Molla A; Olejniczak ET Bioorg Med Chem Lett; 2010 Jan; 20(2):612-7. PubMed ID: 20004576 [TBL] [Abstract][Full Text] [Related]
17. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity. Oishi S; Ito S; Nishikawa H; Watanabe K; Tanaka M; Ohno H; Izumi K; Sakagami Y; Kodama E; Matsuoka M; Fujii N J Med Chem; 2008 Feb; 51(3):388-91. PubMed ID: 18197613 [TBL] [Abstract][Full Text] [Related]
18. Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action. Wang C; Cheng S; Zhang Y; Ding Y; Chong H; Xing H; Jiang S; Li X; Ma L Viruses; 2019 Sep; 11(9):. PubMed ID: 31480738 [TBL] [Abstract][Full Text] [Related]
19. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment. Zhao L; Tong P; Chen YX; Hu ZW; Wang K; Zhang YN; Zhao DS; Cai LF; Liu KL; Zhao YF; Li YM Org Biomol Chem; 2012 Aug; 10(32):6512-20. PubMed ID: 22760295 [TBL] [Abstract][Full Text] [Related]
20. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]